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Abstract  1
The Human papillomavirus (HPV) 16 genome has been extensively studied, although no 2
study has focused on the E1 gene that is implicated in viral DNA replication. After 3
analyzing the E1 region of HPV 16 genomes in 429 cervical samples, 11.2% were found 4
to contain a 63 nucleotides duplication in this region. Sequence analysis of the E6 and the 5
E7 regions has shown that all samples containing this duplication were related to E6-6
G350 variant of the HPV 16 (Chi square test, p=0.0012). A comparison of cervical lesion 7
severity of the examinees having regular or variant E1 genes has shown that the variant 8
group had a significantly (Fischers exact test, p=0.0401) lower percentage of high grade 9
disease cases, suggesting that this particular duplication might reduce the oncogenic 10
potential of HPV 16, and also might clarify the differences of E6-G350 variant 11
oncogenicity observed in European populations. Albeit, a decreased incidence of high 12
grade cervical lesions can be linked to the prevalence of multiple HPV infection, the 13
additional decrease of those cases with the variant E1 gene versus those without (10.5% 14
and 18.6%, respectively) can only be ascribed to the effect of this particular HPV variant. 15
Further research is needed to clarify the biology of these HPV 16 E1 variants.  16
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Introduction 1
Within the family Papillomaviridae, double stranded DNA viruses, more than 100 2
Human papillomavirus (HPV) types are well-characterized based on their genome 3
sequences [de Villiers et al., 2004; Campo 2006]. Of about 40 mucosal (genital) HPV 4
types, approximately 15 are classified as high risk types; they are the necessary 5
etiological factor of cervical cancer, which is the second most common female cancer 6
after breast cancer [Muñoz et al., 2003]. Of all high risk HPV types, HPV 16, genus 7
Alphapapillomavirus, is the most commonly found in nearly 60% of cervical cancer cases 8
worldwide [Clifford et al., 2003b]. It is also known that only a small percentage of HPV 9
16 positive lesions progress to cancer [Moreno et al., 1995; Bosch et al., 2002]; the 10
reason for this still needs to be elucidated.  11
HPV variants are defined as viruses that vary by 2% or less in specified regions of 12
the genome [Bernard et al., 1994], and some have been shown to display different 13
oncogenicity (reviewed in Bernard et al., 2006). Most of the studies on HPV 16 14
variability were concerned with E6 and E7 proteins that are known HPV oncogenes. In 15
addition, while many studies referred to the variability of E2, L1, L2 genes and LCR 16
region, none were found on E1 variability or its relationship with HPV 16 oncogenicity 17
(reviewed in Giannoudis and Herrington, 2001). The E1 gene encodes a multifunctional 18
protein that can bind DNA and interact with the E2 protein and DNA polymerase alpha-19
primase [Chow and Broker, 2006; Wilson et al., 2002]. Furthermore, the E1 protein has 20
ATPase and helicase activities [Hughes and Romanos, 1993] and together with the HPV 21
E2 protein, plays an important role in HPV replication and transcriptional regulation 22
[Chow and Broker, 1994]. Although the E1 gene seems to be relatively well conserved in 23
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most HPV types [Shih-Yen et al., 1992], the goal of this study was to investigate a novel 1
HPV type 16 variant within the E1 gene. 2
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Materials and methods 1
Clinical samples 2
DNA samples were chosen from a collection of cervical specimens gathered 3
previously from women attending the outpatient units of several gynaecology clinics in 4
Zagreb (Croatia) for the purpose of HPV detection and genotyping in accordance with the 5
Croatian protocol for the management of women with precancerous cervical lesions 6
[Ljubojevic et al., 2001]. The cytological diagnosis of cervical specimens was determined 7
according to the Croatian classification of cervical smears “Zagreb 2002” [Ovanin-Rakic 8
et al., 2003] that is in line with the “2001 Bethesda” system for reporting Pap test results.  9
In accordance with examinee cytological diagnosis cervical samples were grouped as 10
follows: 25.4% (109/429) with atypical squamous cells of unknown significance 11
(ASCUS), 20.5% (88/429) with low-grade squamous intraepithelial lesions (LSIL, also 12
designed as cervical intraepithelial neoplasia grade 1, i.e. CIN1), 24.5% (105/429) with 13
high-grade SIL/CIN2, 23.8% (102/429) with HSIL/CIN3 diagnosis, and 5.8% (25/429) of 14
the samples with an unknown diagnosis. For 404 examin es, the age ranged from 17 to 15
69 with an average age of 25, while in 25 cases the age was unknown. 16
HPV detection and typing were performed with consensus and type-specific 17
polymerase chain reaction (PCR) reactions as described previously [Grce et al., 2001]. 18
Briefly, each cervical DNA specimen is amplified by three sets of consensus primers, and 19
type-specific primers for the two most common low-risk HPV types 6 and 11 (common 20
primer pair 6/11) that can be expected in the genital specimens, and also the four most 21
common high-risk HPV types 16, 18, 31 and 33 that can be expected in high-grade 22
cervical lesions [Clifford et al., 2003a].  23
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In this study, a subset of 429 HPV 16 positive samples was analysed further. A 1
total of 307 out of 429 (71.6%) samples were positive for probably only HPV 16 (other 2
less common types, that were not detectable by the assay used, cannot be excluded), 3
while 122 (28.4%) samples were positive for HPV 16 and at least one other HPV type 4
determined by type-specific PCR (i.e. multiple HPV infection: HPV 16 + types 6/11, 18, 5
31 and/or 33; additional other less common HPV types cannot be excluded). The study 6
was approved by the Ethical Board of the Rudjer Boskovic Institute. 7
DNA amplification of the E1 gene of HPV 16 DNA 8
In a previous investigation of HPV 16 viral genome integration (data submitted 9
for publication), the amplification of E1/E2 region by primers designed by Lukaszuk et 10
al. [2003] showed unexpectedly a different amplicon size from that anticipated in 11
approximately 10% of samples (data was not presented). To analyze these unusual PCR 12
products this study was performed.  13
A pair of 16E1-F (5’-CAT AGA GAT GCA GTA CAG G) and 16E1-R (5’-CTC 14
ACC CCG TAT AAC TC) primers was designed in order to amplify the 417 bp from 15
nucleotides 1099 to 1516 of the HPV 16 E1 gene. The PCR was performed in 20 µl16
containing 100 ng of sample DNA, PCR buffer (Promega), 0.2 mM of each dNTP, 2 mM 17
MgCl2, 0.25 µM of each primer and 0.125 U GoTaq DNA polymerase (Promega). Each 18
PCR was carried out (Thermal cycler 2720, Applied Biosystems) under the following 19
conditions: initial denaturation for 10 minutes at 95oC, 35 cycles of denaturation for 30 20
seconds at 95oC, annealing for 30 seconds at 55oC and elongation for 45 seconds (+1 21
second for each cycle) at 72oC, and final elongation at 72oC for 7 minutes.  22
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Aliquots (10 µl) of each PCR product were resolved by electrophoresis in a 2% 1
agarose gel stained with ethidium bromide. The amplicons were identified by UV 2
irradiation of the gels, and photographed by Image Master VDS (Pharmacia Biotech). 3
DNA Amplification of the E6/E7 region 4
For the analysis of the E6 region, the following primer pair was used: 16E6-F (5’- 5
CAC AGT TAT GCA CAG AGC TGC) and 16E6-R (5’-CAT ATA TTC ATG CAA 6
TGT AGG TGT A), amplifying 457 bp region from 141 to 597 of the E6 gene [Sotlar et. 7
al, 2004]. The 20 µl reaction mixture contained 1X PCR buffer (Promega), 2.0 mM 8
MgCl2, 200 µM of each dNTP, 0.15 µM of each primer and 0.125 U GoTaq DNA 9
polymerase (Promega). After the first 5 minutes of denaturation at 950C, 40 cycles of 10
denaturation at 940C for 30 seconds, annealing at 57.50C for 30 seconds, and extension at 11
720C for 30 seconds were applied, followed by final elongation for 7 minutes at 72 0C. 12
Additionally, a second primer pair, 16E6/7-F (5’-CCC ACT GCT GGA CAA 13
CAT GC) and 16E6/7-R (5’-GTG TGC CCA TTA ACA GGT CTT CCA), was used in 14
order to amplify a product of 253 bp at the junction of the E6 and E7 regions, from 548 to 15
801. The 20 µl reaction mixture contained 1X PCR buffer (Promega), 1.5 mM MgCl2,16
100 µM of each dNTP, 0.15 µM of each primer and 0.125 U GoTaq DNA polymerase 17
(Promega). After the first 5 minutes of denaturation at 950C, 35 cycles of denaturation at 18
940C for 15 seconds and annealing-extension at 620C for 4 minutes were applied, 19
followed by final elongation for 7 minutes at 72 0C.  20
In these cases too, aliquots (10 µl) of each PCR product were resolved by 21
electrophoresis in a 2% agarose gel stained with ethidium bromide and analysed on 22
Image Master VDS (Pharmacia Biotech).  23
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DNA sequencing and sequence analysis 1
Approximately 500 ng of each purified PCR product was sequenced at the local 2
core sequencing facility (ABI PRISM 310 Genetic Analyzer, Applied Biosystems) of the 3
Rudjer Boskovic Institute (Zagreb, Croatia), using a BigDye Terminator v1.1 Cycle 4
Sequencing Kit (Applied Biosystems) with both forward and reverse primers. The 7.0.5.2 5
Bioedit version was used for sequence alignment and translation. The referent HPV 16 6
genome sequence was obtained from the NCBI GenBank under accession number 7
K02718, along with sequences of major HPV 16 variants [Yamada et al., 1997]: Asian-8
American (gb|AF402678), East Asian (gb|AF534061), African-1 (gb|AF536180), 9
African-2 (gb|AF472509), and European German (gb|AF536179.1). The referent HPV16 10
E1 protein sequence was obtained from the NCBI protein database under accession 11
number NP_041327.1.  12
Statistical analysis 13 
 The findings were processed manually into Microsoft Excel on a personal 14
computer and the statistical analysis was performed using Fischer’s exact test and Chi-15
square test (GraphPad Prism version 4.00 for Windows, GraphPad Software, San Diego 16
California USA). The p values <0.05 were considered significant. 17
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Results 1
Upon electrophoresis of the E1 HPV 16 amplicons, 88.6% (380/429) of samples 2
had a regular band of expected amplicon size (417 bp), while 11.2% (48/429) had a 3
variant band of approximately 480 bp in size (Table 1). Additionally, there was one 4
sample (0.2%) containing both regular and variant band.  5
Eight samples showing larger and 2 samples showing regular E1 HPV 16 6
amplicons were sequenced to validate the difference in amplicon size and to determine 7
sequence alignment. The sequencing showed that a duplication of 63 nucleotides was 8
present in samples with a larger amplicon, i.e. variant band. A "monomer" sequence of 9
the regular amplicon begins at position 1311 and ends at position 1373, while all variant 10
amplicons contain the "monomer" sequence duplicated in tandem (Figure 1-A). 11
The E1 gene containing the observed insertion of 63 nucleotides, when translated 12
should give rise to an enlarged protein of 670 amino acid residues long. The duplication 13
is "in frame" in all respects in the DNA so the protein has the part of its sequence 14
repeated. The amino acid sequence "monomer" is 21 residues long from amino acid at 15
position 150 to position 170; the duplicated copy begins immediately afterwards (Figure 16
1-B). 17
To verify whether this duplication in the E1 region is a previously unknown 18
feature of some already known HPV variant, parts of the E6 and E7 regions were 19
sequenced in 9 of such samples. The E6 region sequencing revealed that every case 20
resembled the HPV 16 European German type, which has G instead of T at position 350 21
of the genome, while they had no deviations from the referent HPV 16 (K02718 of the 22
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GenBank) sequence in the E7 region; the European German variant had the same 1
sequence as the referent variant in this region, so this was expected. 2
To be able to better understand the differences of samples with the 63 nucleotides 3
duplication in relation to those with the regular E1 sequence, 13 samples without 4
duplication were also analysed in the E6 and E7 regions. For the E6 region, 8 samples 5
were found to be the referent HPV 16 type, 4 were identified as European German 6
variants, having the same substitution as the E1 variant samples, and one was not related 7
to the European variants. Sequencing of the E7 region of the samples without duplication 8
revealed 12 of them to be European variants, similar to the E1 variant samples, and the 9
remaining one was again unrelated to European variants. 10
The association of E1 duplication with G350 mutation (9/9) appears statistically 11
significant (p=0.0012, Chi-square test) when compared with the distribution of G350 12
mutation in samples without the E1 duplication (4/13). 13
The one case unrelated to European variants in both the E6 and E7 sequence 14
analyses had several substitutions in the E6 region (T>A at 286; A>G at 289; C>T at 335; 15
T>G at 350) suggesting it to be related, but not identical to Af1, Af2 or AA variants. It 16
also had 2 additional substitutions in the E7 region, C instead of T at position 789 and G 17
instead of T at position 795 of the HPV16 referent genome. However, even with these 18
additional differences it was impossible to determine the exact variant group to which this 19
sample belongs, because there were other sites in the sequence that were identical to the 20
referent sequence and which should be different in either the Af1, Af2 or AA variants.  21
There was no significant (Chi-square, p=0.0647) association between multiple 22
infections and variant status (Table 1). However, if the one sample containing both, 23
regular and variant HPV 16 E1 gene is included in the group of both those with and those 24
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without the 63 nucleotide duplication, the difference becomes significant with p=0.0445 1
(Chi-square). In addition, if this sample is only ascribed to the sample group with the 2
variant HPV 16 E1 gene the difference is also significant and even slightly higher with 3
p=0.0413 (Chi-square).  4
The distribution of regular or variant HPV 16 E1 gene according to examinee 5
cytological diagnosis shows a significant (Fischers exact test, p=0.0401) association 6
between the group of samples with the variant HPV 16 E1 gene and the decrease of the 7
cervical lesion grades, especially from CIN1 to CIN3. On the other hand, an increase of 8
the cervical lesion grade is observed in the group of samples with the regular HPV 16 E1 9
gene, but this is most apparent for samples containing a single HPV 16 infection and of 10
lesser extent than the decrease observed for multiple infections with variant HPV 16 E 1 11
gene (Figure 2 and Table 2). 12
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Discussion 1
As a relatively large proportion (11.2%) of the analysed samples was shown to 2
have the 63 nucleotide duplication in the E1 gene of the HPV 16 genome, further 3
investigation of this region and its biological properties are needed.  4
The region of the E1 gene in which the 63 nucleotide duplication was observed 5
has no function associated with it, except inconclusively H1 histone binding [Wilson et 6
al., 2002]. Swindle and Engler (1998) have shown that the first 185 N-terminal amino 7
acids of HPV 11 E1 protein bind H1 histone. Therefore, the duplication of amino acids 8
from 150 to 170 might influence this binding in affected HPV 16 E1 proteins. In addition, 9
Amin et al. (2000) found that HPV E1 proteins lacking the N-terminal domain are less 10
effective in supporting HPV replication than full length proteins. Additionally, Yasugi et 11
al. (1997) earlier suggested that amino acids 144-420 also play a role in E1-E2 12
interactions at physiological temperatures, and this might be disrupted in samples 13
harbouring the observed duplication. 14
To assess whether the variant E1 protein has any impact on the oncogenic 15
potential of the supposed HPV 16 variant, samples were sorted in groups according to the 16
presence of duplication. For both groups, data on cytological diagnosis and examinee age 17
were retrieved from the database (Table 2). The group with the regular E1 gene was 18
significantly less associated with CIN1 and more with CIN3 cases than the group with the 19
variant E1 gene (Figure 2). As the mean age of both groups is the same, the age is 20
unlikely to be the cause of this decrease in lesion grade.  21
Some authors link the presence of multiple HPV infections with an increased 22
severity or increased risk of lesions of the cervices [van der Graaf et al., 2002; Ho et al., 23
1998; Morrisonet al., 1991; Sasagawaet al., 2001]. On the other hand, other studies report 24
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no significant additional risk of cervical intraepithelial neoplasia cervical cancer when 1
comparing patients with single or multiple infections [Bosch et al., 2002; Herrero et al., 2
2000]. In addition, Gargiulo et al. (2007) report finding multiple HPV infections 3
significantly less often in severe dysplasia and cervical cancer. Thus, the presence of 4
multiple infections in the sample pool of this study might confound these findings as a 5
lower disease grade might be associated with multiple HPV infection and not variant 6
HPV 16. To address this issue, samples were split depending on the status of HPV 16 7
infection (probable single and confirmed multiple with HPV 6/11, 18, 31 and/or 33). In 8
the sample pool, the incidence of CIN3 was the highest in cases with probably single 9
infection with HPV 16 without duplication, and the lowest in cases containing multiple 10
infections including variant HPV 16 with duplication (Table 2 and Figure 2). The 11
findings presented in this study are in line with the findings of Gargiulo et al. (2007), as 12
when the group of samples with the variant HPV 16 E1 gene were disregarded, multiple 13
infection samples were less associated with CIN3 cases than cases with probable single 14
infections, but this difference was not significant (Fischer’s exact test, p=0.2424). While 15
a decreased incidence of CIN3 can be linked to the prevalence of multiple HPV infection, 16
the additional decrease of CIN3 incidence in samples with multiple HPV infection and 17
with the variant versus regular HPV 16 E1 gene (10.5% and 18.6%, respectively) can 18
only be ascribed to the effect of this particular HPV 16 variant (Table 2).  19
Sequencing results revealed that all samples with the variant HPV 16 E1 gene for 20
which E6/E7 was analysed, had sequences identical to the European German variant, 21
having T at nucleotide 350 replaced with G (often referred to as E6-350G or L83V 22
variant). As 4 of 13 samples with the regular HPV 16 E1 gene were also shown to be the 23
European German variant with the same substitution, it is likely that the decreased 24
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oncogenicity in the group of samples with the variant HPV 16 E1 gene comes from the 1
reduced oncogenicity of the E6-350G subvariant containing the 63 nucleotides 2
duplication in the E1 gene relative to “normal” E6-350G or referent HPV 16 variants. 3
Moreover, as the group of samples with the regular HPV 16 E1 gene was mostly 4
determined to be the European variant, the association of those samples with CIN3 is 5
probably due the expected oncogenicity of the referent European HPV 16 variant [Zehbe 6
et al., 1998a] and not due to the large presence of other more oncogenic variants.  7
This finding is interesting, as the “normal” E350G variant was previously 8
described as either strongly associated with cervical cancer in some European populations 9
like Swedish or French [Zehbe et al 1998a; Grodzki et al 2006] or not clearly associated 10
with cervical cancer in others [Bontkes et al., 1998; Zehbe et al., 1998b; Brady et al., 11
1999; Nindl et al., 1999; van Duin et al., 2000]. It was suggested that genetic differences 12
between populations, in particular in the human leukocyte antigens, contribute to this 13
difference [Zehbe et al., 1998b, 2001]. Another study, focused on in vitro evaluation of 14
E6 variants, has shown that this E350G variant has the same ability to degrade p53 and 15
Bax levels as the referent E6 protein. However, this variant was shown to have a slightly 16
increased capability of inhibiting serum/calcium induced differentiation, which led the 17
authors to believe that this variant might have increased pathogenicity [Asadurian et al., 18
2007]. This in vitro study shows that the E350G variant does not have lesser oncogenicity 19
due to functional changes to the E6 protein, eliminating this mutation as a source of 20
disagreement between studies in different populations.  21
In this study, the E350G variant exhibits reduced oncogenicity, which is 22
consistent with studies done in geographically closer populations. However, this effect 23
was more clearly observed in samples with the variant HPV 16 E1 gene suggesting that 24
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the different oncogenicity of variants characterized as E350G in different European 1
populations might be assigned to the new subvariant containing the 63 nucleotide 2
duplication within the E1 gene that was observed, or some other genome change in 3
addition to possible genetic differences in European populations. It would be interesting 4
to investigate whether the samples in studies showing no association between E350G and 5
cervical cancer also contain this duplication in the E1 gene, as this region of the HPV 6
genome was not evaluated at all. 7
The 63 nucleotide duplication within the E1 gene observed in this study was 8
previously described only once by Dong et al. (2000), who analysed 28, HPV 16 positive, 9
cervical cancer samples for other reasons in the Chinese population. From their 10
unexpected chance observation and our focused study of this possible new variant, it 11
seems to have a world-wide distribution and is not an isolated local case on either 12
continent. Neither their group nor this one has followed the examinees after cervical 13
specimen collection, so no firm conclusions regarding the long-term effect on the 14
persistence of infection and its oncogenic potential are possible.  15
Data presented in this study suggests that the HPV 16 variant with the 63 16
nucleotide E1 duplication might exhibit decreased oncogenicity, especially in case of the 17
HPV 16 G350 variant that was suggested to have increased oncogenicity. This study 18
might also encourage further research in the up-to-now neglected variability of the HPV 19
16 E1 region and its effect on disease progression.  20
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Table 1. Distribution of cervical specimens containing the regular amplicon and those 1
containing a 63 nucleotides duplication in the HPV 16 E1 gene  2
3
Table 2. Distribution of examinee cytological diagnosis and age in different sample 4
groups 5
6
Figure 1. A) Nucleotide sequence alignment of samples containing regular (RB) or 7
variant band (VB) of the HPV 16 E1 gene in comparison with the referent HPV 16 8
sequence published in GenBank under accession number K02718; HPV 16 is the referent 9
sequence; VB1-VB7 are representative sequences of samples with the 63 nucleotides 10
duplication in the HPV 16 E1 gene; RB1 and RB2 are sequences of 2 samples with 11
regular sequence alignment; the duplicated sequence is underlined in the HPV 16 and 12
VB1 sequences. B) Protein sequence alignment of sequences derived by translating 13
nucleotide sequences of VB samples (containing the 63 nucleotide duplication) to the 14
referent HPV 16 E1 protein sequence from the NCBI protein database accessible under 15
accession number NP_041327.1; the duplicated sequence is underlined 16
17 
Figure 2. Incidence of A) regular and B) variant band (63 nucleotide duplication) of the 18
HPV 16 E1 gene according to cytological diagnosis and HPV 16 status (probable single 19
and multiple infection with confirmed HPV 6/11, 18, 31 and/or 33)  20
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Table 1. Distribution of cervical specimens containing the normal and variant HPV 16 
E1gene 
 
Number of cervical samples (%) 
regular* variant** regular and 
variant 
Total 
Single HPV 16 
infection 
278 (90.6) 29 (9.4) 0 (0) 307 (71.6) 
Multiple HPV 
infection*** 
102 (83.6) 19 (15.6) 1 (0.8) 122 (28.4) 
All cases 380 (88.6) 48 (11.2) 1 (0.2) 429 (100) 
*regular HPV 16 E1 amplicon size (417 bp); **larger HPV 16 E1 amplicon size 
(480 bp) containing a 63 nucleotides duplication; ***HPV 16 with 6/11, 18, 31 
and/or 33 
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Table 2. Distribution of examinee cytological diagnosis and age in different sample groups
Examinee cytological diagnosis***27 Patient age (years)
Sample group*
Number of 
samples**
(%) UnknownN (%)
ASCUS
N (%)
LSIL
CIN1
N (%)
HSIL
CIN2
N (%)
HSIL
CIN3
N (%)
Average 
age
(range)
Unknown
 N (%)
Samples with normal 
E1 HPV 16 gene
380
(88.8%)
21
(5.5%)
101
(26.6%)
73
(19.2%)
91
(23.9%)
94
(24.7%)
29
(18-69)
23
(6.0%)
Single HPV 16 
infection 
278
(64.8)
12
(4.3)
70 
(25.2)
54
(19.4)
67
(24.1)
75
(27.0)
30
(18-54)
19
(6.8)
Multiple HPV 
infection
102
(24.0)
9
(8.8)
31 
(30.4)
19
(18.6)
24
(23.5)
19
(18.6)
28
(18-69)
4
(3.9)
Samples with variant
E1 HPV 16 gene
48
(11.2%)
4
(8.3%)
8
(16.7%)
15
(31.3%)
14
(29.2%)
7
(14.6%)
29
(17-57)
2
(4.2%)
Single HPV 16 
infection 
29
(6.8)
3
(10.3)
4
(13.8)
8
(27.6)
9
(31.0)
5
(17.2)
28
(17-50)
1
(3.4)
Multiple HPV 
infection
19
(4.4)
1
(5.3)
4
(21.1)
7
(36.8)
5
(26.3)
2
(10.5)
30
(19-57)
1
(5.3)
Total 428(100)
25
(5.8)
109
(25.5)
88
(20.6)
105
(24.5)
101
(23.6)
29
(17-69)
25
(5.8)
*normal HPV - regular HPV 16 E1 amplicon size (417 bp), variant HPV - larger HPV 16 E1 amplicon size (480 bp) containing a
63 nucleotides duplication, multiple HPV infection - HPV 16 with 6/11, 18, 31 and/or 33; **one sample with a normal and a
variant HPV 16 E1 amplicon corresponding to a 23-year old woman with CIN3 and multiple HPV infection was excluded; ***
ASCUS - atypical squamous cells of unknown significance, LSIL - low-grade squamous intraepithelial lesions, CIN1 - cervical
intraepithelial neoplasia grade 1, HSIL - high-grade squamous intraepithelial lesions, CIN2/3 – CIN grade 2 or 3
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Figure 1. A) Nucleotide sequence alignment of samples containing regular (RB) or variant 
band (VB) of the HPV 16 E1 gene in comparison with the referent HPV 16 sequence 
published in GenBank under accession number K02718; HPV 16 is the referent sequence; 
VB1-VB7 are representative sequences of samples with the 63 nucleotides duplication in 
the HPV 16 E1 gene; RB1 and RB2 are sequences of 2 samples with regular sequence 
alignment; the duplicated sequence is underlined in the HPV 16 and VB1 sequences. B) 
Protein sequence alignment of sequences derived by translating nucleotide sequences of 
VB samples (containing the 63 nucleotide duplication) to the referent HPV 16 E1 protein 
sequence from the NCBI protein database accessible under accession number 
NP_041327.1; the duplicated sequence is underlined 
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Figure 2. Incidence of A) regular and B) variant band (63 nucleotide duplication) of the 
HPV 16 E1 gene according to cytological diagnosis and HPV 16 status (probable single 
and multiple infection with confirmed HPV 6/11, 18, 31 and/or 33) 
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